X'e bağlı agamaglobulinemi hastalarında uygulanan COVID-19 tedavi prosedürleri
Küçük Resim Yok
Tarih
2024
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Malatya Turgut Özal Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: COVID-19 pandemisi 2019 yılında başlayan ve birçok kişinin ölümüne neden olan küresel bir salgındır. X'e bağlı agamaglobulinemi (XLA) B hücrelerinin oluşumunu engelleyen genetik bir hastalıktır. İmmünoglobülin replasmanı ile ömür boyu tedavi gerektirir. Bu bireylerde olgun B hücrelerinin olmamasının COVID-19 seyrini olumsuz yönde etkileyebileceği düşünülmektedir. Toplumdaki bazı bireylerde olduğu gibi bu bireylerde COVID-19 enfeksiyonunu hafif atlatanlar görülmüştür. Bu çalışmada PCR ile COVID-19 tanısı konulan XLA hastalarının COVID-19 süreçleri ve bu hastalara uygulanan tedaviler ele alınmıştır.Materyal ve Metot: Bu derlemede 15 Kasım 2021'e kadar PubMed, Web of Science, TRDizin ve Dergi Park web sitelerinde yayınlanan çalışmalar ele alındı. İngilizce ve Türkçe dilinde yapılmayan ve tam metni olmayan çalışmalar elendi. Bu çalışmalar arasından yalnızca XLA hastalarına ait COVID-19 olgu vakaları seçildi. Seçilen 16 makalede toplam 22 vaka incelendi.Bulgular: Vakaların büyük çoğunluğunun COVID-19 süreçlerini daha ağır ve uzun süreli geçirdiği gözlemlendi. Bu hastalarda tedavi için antiviraller, anti-SARS-CoV-2 nötralize edici antikorlar ve immünomodülatör ajanlar kullanıldığı belirlendi.Sonuç: XLA sahip bireylerde tedavi için antiviraller ve anti-SARS-CoV-2 nötrolize edici antikorların etkili olduğu düşünülmüştür.
Background: COVID-19 is a pandemic that started in 2019 and caused the death of many people. X-linked agammaglobulinemia (XLA) is a genetic disease that prevents the formation of B cells. This disease requires lifelong treatment with immunoglobulin replacement. It is thought that the absence of mature B cells in these individuals may adversely affect the course of the disease. As in some individuals in the society, it was seen that these individuals survived the disease mildly. In this study, the COVID-19 processes of XLA patients who were diagnosed with PCR and the treatments applied to these patients were discussed.Materials and Methods: In this review, studies published on PubMed, Web of Science, TRDizin and Dergi Park websites until November 15, 2021 were discussed. Studies that were not made in English and Turkish languages and did not have full text were eliminated. Among these studies, only COVID-19 cases of XLA patients were selected. 22 cases were analyzed in 16 selected articles.Results: It was observed that the vast majority of cases had more severe and prolonged COVID-19 processes. Antivirals, anti-SARS-CoV-2 neutralizing antibodies and immunomodulatory agents have used for treatment in these patients.Conclusions: Antivirals and anti-SARS-CoV-2 neutralizing antibodies have been considered effective for treatment in individuals with XLA.
Background: COVID-19 is a pandemic that started in 2019 and caused the death of many people. X-linked agammaglobulinemia (XLA) is a genetic disease that prevents the formation of B cells. This disease requires lifelong treatment with immunoglobulin replacement. It is thought that the absence of mature B cells in these individuals may adversely affect the course of the disease. As in some individuals in the society, it was seen that these individuals survived the disease mildly. In this study, the COVID-19 processes of XLA patients who were diagnosed with PCR and the treatments applied to these patients were discussed.Materials and Methods: In this review, studies published on PubMed, Web of Science, TRDizin and Dergi Park websites until November 15, 2021 were discussed. Studies that were not made in English and Turkish languages and did not have full text were eliminated. Among these studies, only COVID-19 cases of XLA patients were selected. 22 cases were analyzed in 16 selected articles.Results: It was observed that the vast majority of cases had more severe and prolonged COVID-19 processes. Antivirals, anti-SARS-CoV-2 neutralizing antibodies and immunomodulatory agents have used for treatment in these patients.Conclusions: Antivirals and anti-SARS-CoV-2 neutralizing antibodies have been considered effective for treatment in individuals with XLA.
Açıklama
Anahtar Kelimeler
Clinical Sciences, Klinik Tıp Bilimleri
Kaynak
Journal of Medical Topics and Updates
WoS Q Değeri
Scopus Q Değeri
Cilt
3
Sayı
1
